Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study

Rhea-AI Summary

Alpha Tau (Nasdaq: DRTS) reported final results from its first-in-human pancreatic ductal adenocarcinoma (PDAC) study in Montreal, with data presented at ASCO GI 2026 (Jan 8–10, 2026).

Key clinical readouts: 22% objective response rate (ORR) and 81% disease control rate (DCR) across 32 patients (or 23% ORR and 87% DCR excluding the first two low‑dose patients). Immune marker analysis in 23 patients showed no significant worsening of NLR, PLR, CD4/CD8 ratio, or CRP one month post‑treatment, plus a dramatic drop in IL‑6 (p<0.000001), suggesting immune preservation and a potential anti‑inflammatory effect. The company is continuing U.S. multi‑center combination testing in the IMPACT trial (NCT06698458).

Positive

• 81% DCR across 32 PDAC patients
• 23% DCR when excluding first two low‑dose patients
• 22% ORR across all treated patients
• No significant change in NLR/PLR/CD4:CD8/CRP one month post‑treatment
• Dramatic IL‑6 reduction (p<0.000001) suggesting lower inflammation
• Feasible endoscopic ultrasound delivery with a reported strong safety profile

Negative

• Small pilot cohort of 32 patients, limiting statistical power
• Heterogeneous population: many patients had prior chemotherapy, complicating attribution of benefit

Key Figures

Patients treated 32 patients Montreal first-in-human pancreatic PDAC study

Objective Response Rate 22% All 32 PDAC patients in Montreal trial

Disease Control Rate 81% All 32 PDAC patients in Montreal trial

Objective Response Rate (adj.) 23% Excluding first two low-dose feasibility patients

Disease Control Rate (adj.) 87% Excluding first two low-dose feasibility patients

Patients with lab data 23 patients Immune and inflammatory marker analysis cohort

Follow-up interval 1 month Post-Alpha DaRT immune marker assessment

IL-6 p-value p<0.000001 Dramatic drop in IL-6 cytokine levels after treatment

Market Reality Check

$6.93 Last Close

Volume Volume 208,701 is below the 20-day average of 295,569, indicating modest participation in the 8.07% move. normal

Technical Price at $5.22 matches the 52-week high and is trading above the 200-day MA at $3.47.

Peers on Argus

While DRTS gained 8.07%, key biotech peers like ALDX, ADCT, AUTL, IMRX and TECX showed declines (e.g., ALDX -9.79%), pointing to a stock-specific reaction to the clinical data rather than a sector-wide move.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 18	Conference appearance	Positive	+4.2%	J.P. Morgan 2026 Healthcare Conference corporate overview announcement.
Dec 09	Clinical trial update	Positive	+8.7%	First patient treated in U.S. pilot study for recurrent glioblastoma.
Dec 04	Clinical data preview	Positive	+4.6%	Acceptance of two pancreatic Alpha DaRT abstracts for 2026 ASCO GI.
Dec 02	Regulatory clearance	Positive	+2.4%	FDA IDE approval for locally recurrent prostate cancer pilot trial.
Dec 01	Investor outreach	Neutral	-4.8%	Planned presentations at two December 2025 investor conferences.

Pattern Detected

Recent company-specific updates, especially on clinical programs and conferences, have generally been followed by positive price reactions.

Recent Company History

Over the past weeks, Alpha Tau has consistently reported progress across its Alpha DaRT® pipeline. On Dec 2, 2025, the company received FDA approval of an IDE for a recurrent prostate cancer trial, followed by pancreatic cancer abstract acceptance on Dec 4, first-patient treatment in a U.S. glioblastoma study on Dec 9, and a J.P. Morgan conference presentation announced on Dec 18. Most of these events were associated with positive one-day price moves, suggesting the market has been responsive to clinical and visibility milestones ahead of today’s detailed pancreatic data.

Market Pulse Summary

The stock surged +11.9% in the session following this news. A strong positive reaction aligns with prior patterns where Alpha Tau’s clinical and regulatory milestones often preceded gains of several percent. The detailed Montreal pancreatic data, including 81–87% disease control rates and a highly significant IL-6 p-value of <0.000001, provided concrete efficacy and immune-preservation signals. With shares at a 52-week high of $5.22 and trading above the $3.47 200-day MA, future durability would depend on how subsequent trials replicate these findings and how investors weigh ongoing development risks.

Key Terms

pancreatic ductal adenocarcinoma medical

"exploring the use of Alpha DaRT in treating pancreatic ductal adenocarcinoma (PDAC)."

A fast-growing cancer that starts in the cells lining the pancreas’ small ducts; it is the most common and aggressive form of pancreatic cancer. It matters to investors because its severity and limited treatment options drive high unmet medical need, large potential markets for effective drugs or diagnostics, and strong sensitivity of company valuations to clinical trial results, regulatory approvals, or changes in treatment guidelines—similar to how fixing a main leak can prevent major damage in a building.

objective response rate medical

"The results demonstrate a 22% objective response rate (ORR) and an 81% disease"

The objective response rate (ORR) is the percentage of patients in a clinical trial whose tumors measurably shrink or disappear according to preset rules. Investors use it as a quick, objective signal of a drug’s ability to produce a clear treatment effect—like counting how many plants visibly respond after applying a new fertilizer—and higher ORR can improve odds of regulatory approval, commercial success, and company valuation.

disease control rate medical

"22% objective response rate (ORR) and an 81% disease control rate (DCR) across all"

The disease control rate is the share of patients in a clinical trial whose cancer or condition either shrinks or stops getting worse for a specified period after treatment. Think of it like the percentage of people for whom a treatment hits pause or nudges back the problem rather than letting it progress; higher rates suggest the therapy can meaningfully limit disease, which matters to investors assessing a drug’s potential efficacy and commercial value.

neutrophil-to-lymphocyte ratio medical

"no significant change in Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte"

The neutrophil-to-lymphocyte ratio (NLR) is a simple number calculated from a routine blood test that compares two types of white blood cells: neutrophils (first responders in inflammation) and lymphocytes (cells tied to long-term immune response). Like measuring the relative sizes of two teams in a tug-of-war, a higher NLR often signals more systemic inflammation or stress and can predict disease severity or treatment response — information investors use to gauge the likely success, market potential, or regulatory risk of medical therapies and clinical trials.

platelet-to-lymphocyte ratio medical

"no significant change in Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio,"

The platelet-to-lymphocyte ratio is a simple blood test result that compares the number of platelets (cells involved in clotting) to lymphocytes (a type of white blood cell). Investors care because changes in this ratio are used in medical studies as a sign of inflammation or disease severity and can influence the perceived effectiveness of drugs, the outlook for clinical trials, regulatory reviews, and the commercial prospects of healthcare products—like a dashboard light that signals potential trouble or recovery.

cd4/cd8 t-cell ratio medical

"Platelet-to-Lymphocyte Ratio, CD4/CD8 T-cell ratio, or C-Reactive Protein levels,"

The CD4/CD8 T-cell ratio is a laboratory measure comparing the number of helper T cells (CD4) to killer T cells (CD8), which together coordinate and carry out immune responses. Investors watch this ratio because it acts like a health-check for the immune system—changes can signal how well an immunotherapy or vaccine is working, the risk of infection or disease progression, or potential safety issues in clinical trials.

c-reactive protein medical

"CD4/CD8 T-cell ratio, or C-Reactive Protein levels, demonstrating immune system"

C-reactive protein (CRP) is a blood biomarker that rises when the body has inflammation or infection, acting like a smoke detector that signals something is wrong. For investors, CRP matters because it is used in clinical tests and drug trials to show whether treatments reduce inflammation, can influence regulators’ and doctors’ decisions, and therefore affects the commercial prospects of diagnostics and therapeutic products.

cytokine medical

"a dramatic drop in levels of IL-6 cytokine (p<0.000001), a key mediator"

Small proteins produced by cells that act as chemical messengers to coordinate immune and inflammatory responses, like text messages or traffic signals telling cells when to activate, calm down, or move. Investors care because cytokines are common drug targets and biomarkers; changes in cytokine activity can determine a therapy’s effectiveness, safety, regulatory approval, and market potential, so trial results or safety signals tied to cytokines often drive stock moves.

AI-generated analysis. Not financial advice.

- Final results from first pancreatic cancer study in Montreal demonstrate 81% disease control rate, or 87% excluding the first two patients -

- Immune markers demonstrate immune system preservation not typical of conventional radiation therapy treatments, as well as potential anti-inflammatory effect -

- Alpha DaRT currently being studied together with first-line chemotherapy in U.S. multi-center pilot trial for newly diagnosed pancreatic cancer -

JERUSALEM, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT^® today announced the release of final results from its first-in-human pancreatic cancer study in Montreal, Canada exploring the use of Alpha DaRT in treating pancreatic ductal adenocarcinoma (PDAC). The results have been published as two abstracts and will be presented at the upcoming 2026 ASCO Gastrointestinal Cancers Symposium in San Francisco, January 8 – 10, 2026.

Study Principal Investigator Corey Miller, MD, MSc, Director of Therapeutic Endoscopy of the Division of Gastroenterology of the JGH, Assistant Professor of Medicine at McGill University, Associate Researcher at the Lady Davis Institute, will lead a presentation entitled “Feasibility, Safety and Efficacy of Endoscopic Ultrasound-Guided Alpha Radiotherapy for Advanced Pancreatic Cancer: A Pilot Study” with final clinical results of the Company’s trial. In the trial, 32 patients with Stage II, III or IV PDAC were treated, many of whom had one or more prior rounds of chemotherapy. The results demonstrate a 22% objective response rate (ORR) and an 81% disease control rate (DCR) across all 32 patients treated in the study, or 23% ORR and 87% DCR when excluding the first two patients, who were deliberately given low dosages in order to examine feasibility and safety only.

The Company is further exploring the use of Alpha DaRT in treating PDAC in its U.S. multi-center pancreatic cancer pilot study, known as IMPACT (Intratumoral Pancreatic Alpha Combination Trial), evaluating the safety, feasibility, and efficacy of Alpha DaRT in combination with chemotherapy for patients with newly diagnosed unresectable locally advanced or metastatic pancreatic adenocarcinoma, as well as in other clinical studies in Europe. Additional information about the IMPACT trial can be found at https://clinicaltrials.gov/study/NCT06698458.

“We are very excited about the results of the study, in which we were the first clinicians to deliver Alpha DaRT via endoscopic ultrasound into the pancreas,” added Dr. Miller. “The results indicate that Alpha DaRT is a technically feasible treatment of pancreatic cancer, with a strong safety profile and encouraging local disease control. We look forward to further exploration of the use of Alpha DaRT for PDAC patients in the IMPACT trial as well as future trials, with the potential to generate a meaningful data set focused on a specific patient population with newly diagnosed disease.”

In addition, in a presentation entitled “Inflammatory and Immune Marker Dynamics following Intratumoral Alpha DaRT for Pancreatic Cancer”, Kim Anh Ma, MD, Assistant Professor of Oncology at Jewish General Hospital in Montreal, will present results showing the immune-preserving profile of Alpha DaRT in PDAC, based on immune markers as well as inflammatory indices known to be negative prognostic indicators, and which typically worsen after other forms of radiation therapy. In a study of 23 PDAC patients treated with Alpha DaRT who had complete laboratory data, one month following Alpha DaRT treatment, investigators observed no significant change in Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, CD4/CD8 T-cell ratio, or C-Reactive Protein levels, demonstrating immune system preservation not typical of conventional radiation therapy treatments. Moreover, low post-treatment levels of some of these indices were associated with favorable disease control. Furthermore, a dramatic drop in levels of IL-6 cytokine (p<0.000001), a key mediator of inflammation, suggested a potential reduced inflammatory effect.

Dr. Ma noted, “It is quite unique to find a radiation therapy with reduced inflammatory profile and no observed increase in negative prognostic factors, typically linked to radiation-induced lymphopenia. This may enable, or even support, other systemic therapies, such as immunotherapy, and may also help explain anecdotes where systemic response to chemotherapy appeared to improve after insertion of Alpha DaRT into the primary tumor in the pancreas.”

Uzi Sofer, CEO of Alpha Tau, stated, “Exploring the treatment of pancreatic cancer remains a cornerstone of our strategy for Alpha DaRT, with multiple clinical trials being pursued in parallel, led by our flagship IMPACT trial, which continues to see an excellent pace of recruitment. We look forward to generating further data in this indication in 2026 and forging ahead toward a potential future approval in this key indication.”

About Alpha Tau Medical Ltd. 

Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.

About Alpha DaRT^®

Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. When used herein, words including “anticipate,” “will,” “plan,” “may,” “continue,” and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to the Alpha DaRT treatment in pancreatic patients, including the potential benefits and associated risks, future applications and uses, the IMPACT study and potential indication approvals , are forward-looking. All forward-looking statements are based upon Alpha Tau’s current expectations and various assumptions. Alpha Tau believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Alpha Tau may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation: (i) Alpha Tau’s ability to receive regulatory approval for its Alpha DaRT technology or any future products or product candidates; (ii) Alpha Tau’s limited operating history; (iii) Alpha Tau’s incurrence of significant losses to date; (iv) Alpha Tau’s need for additional funding and ability to raise capital when needed; (v) Alpha Tau’s limited experience in medical device discovery and development; (vi) Alpha Tau’s dependence on the success and commercialization of the Alpha DaRT technology; (vii) the failure of preliminary data from Alpha Tau’s clinical studies to predict final study results; (viii) failure of Alpha Tau’s early clinical studies or preclinical studies to predict future clinical studies; (ix) Alpha Tau’s ability to enroll patients in its clinical trials; (x) undesirable side effects caused by Alpha Tau’s Alpha DaRT technology or any future products or product candidates; (xi) Alpha Tau’s exposure to patent infringement lawsuits; (xii) Alpha Tau’s ability to comply with the extensive regulations applicable to it; (xiii) the ability to meet Nasdaq’s listing standards; (xiv) costs related to being a public company; (xv) changes in applicable laws or regulations; and the other important factors discussed under the caption “Risk Factors” in Alpha Tau’s annual report filed on form 20-F with the SEC on March 12, 2025, and other filings that Alpha Tau may make with the United States Securities and Exchange Commission. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While Alpha Tau may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing Alpha Tau’s views as of any date subsequent to the date of this press release.

Investor Relations Contact: 

IR@alphatau.com

FAQ

What were the key results for Alpha Tau (DRTS) at ASCO GI 2026 for pancreatic cancer?

Alpha Tau reported a 22% ORR and 81% DCR across 32 PDAC patients, or 23% ORR and 87% DCR excluding the first two low‑dose patients.

How did Alpha DaRT affect immune and inflammatory markers in the Montreal PDAC study?

In 23 patients with complete labs, investigators saw no significant change in NLR, PLR, CD4:CD8, or CRP one month post‑treatment and a dramatic IL‑6 drop (p<0.000001), indicating immune preservation and lower inflammation.

What is the design status of Alpha Tau’s U.S. pancreatic trial (DRTS)?

Alpha Tau is evaluating Alpha DaRT combined with first‑line chemotherapy in a U.S. multi‑center pilot trial called IMPACT (NCT06698458) for newly diagnosed unresectable or metastatic PDAC.

How was Alpha DaRT delivered in the Montreal pancreatic study presented at ASCO GI 2026?

Investigators delivered Alpha DaRT via endoscopic ultrasound into the pancreas, reporting technical feasibility and a strong safety profile.

Do the Montreal results show improved systemic response to chemotherapy after Alpha DaRT?

Investigators reported anecdotes of apparent improved systemic chemotherapy response after Alpha DaRT insertion, but the release presents these as observational comments rather than definitive controlled data.

When and where were the Montreal pancreatic study results for DRTS presented?

The final results were published as two abstracts and presented at ASCO Gastrointestinal Cancers Symposium, Jan 8–10, 2026 in San Francisco.